Patients diagnosed with a systemic inflammatory disease are at increased risk for developing AD, while TNF blocking agents were associated with decreased risk for co-morbid AD in real-world patients diagnosed with RA or psoriasis. This evidence concerns the gene TNF and rheumatoid arthritis.